#USA #Salt Lake City #Molecular Diagnostics #Co-Diagnostics #CODX

Co-Diagnostics Announces Q3 2026 Financial Results

Co-Diagnostics, Inc. (NASDAQ: CODX), a pioneering company in molecular diagnostics, has officially declared its plan to release its financial results for the third quarter of 2026 on November 12, 2026. This announcement comes as part of the company’s ongoing commitment to transparency and engagement with its stakeholders.

Key Details About the Event

Following the market's close, Co-Diagnostics will share its Q3 financial performance, offering insights into its operational strategies and future outlook. The conference call will also feature key members of the management team, including Dwight Egan, Chief Executive Officer, and Daniel Bohrer, Executive Vice President of Finance and Accounting.

This live conference call is scheduled for 4:30 p.m. ET on the same day. Interested analysts and stakeholders can tune into the discussion through the Company’s webcast portal, located on the Events Webcasts page. For those who prefer to join via phone, they may dial 1-888-880-3330 (toll-free) or 1-646-357-8766 (toll) to participate directly.

Webcast Accessibility

For analysts who are unable to join the call in real-time, Co-Diagnostics has ensured that the session will be recorded, allowing participants to access it later through the Company’s official website. This initiative enables stakeholders to stay updated on financial matters at their convenience.

About Co-Diagnostics

Founded in Utah, Co-Diagnostics, Inc. stands out in the healthcare industry with its unique, patented platform for developing molecular diagnostic tests. The advanced technologies designed and manufactured by Co-Dx are known for their versatility and effectiveness, particularly in the analysis of nucleic acid molecules, such as DNA and RNA. This capability has solidified Co-Diagnostics' position as a leader in providing innovative diagnostic solutions.

The company’s cutting-edge technology is continuously utilized for various applications beyond infectious diseases, including the development of personalized medicine. In recent years, they have also focused on enhancing their point-of-care testing capabilities, although these are currently subject to regulatory review before commercialization.

With a strong emphasis on innovation, Co-Diagnostics is dedicated to delivering the highest standards of diagnostics technologies across multiple disease states, ensuring that healthcare providers are equipped with the necessary tools for timely and accurate diagnosis.

As the date approaches for the much-anticipated financial results announcement, stakeholders remain eager to hear about the Company's performance and future directions in an ever-evolving healthcare landscape. Through its proactive communication and commitment to innovation, Co-Diagnostics continues to make significant strides in the field of molecular diagnostics.

In summary, mark your calendars for November 12, as Co-Diagnostics prepares to unveil its third quarter results, offering valuable insights into its ongoing contributions to the diagnostics industry.

For more information about the webcast and financial results, please visit the Co-Diagnostics official website.